Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots ...

This article discusses the Anti-Kickback Statute and the False Claims Act. "When coupled with the False Claims Act (FCA), the AKS turns into a potent civil enforcement tool that carries many of the ...

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.

By Ludwig Burger and Ariane Luthi (Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now ...

The pharma giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to boost its ...

Blackstone Life Sciences has sold Anthos Therapeutics to Novartis for up to $3.1 billion. Anthos is a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the ...